BioCentury

8:00 AM GMT, Feb 2, 2004
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Plucked from the discard pile

Bristol-Myers Squibb Co. may have jumped the gun when it dropped development of tesmilifene after the compound failed to improve response rates and progression-free survival in a Phase III breast cancer trial. As it turns out, tesmilifene actually increased overall survival.

Now YM Biosciences Inc. is preparing another go with tesmilifene in breast cancer, after initially picking up the discarded compound based on its promising activity in prostate cancer.

In 2000, YM

Read the full 714 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.